1196-90-3

Usage

Uses

Used in Organic Synthesis:
METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE is used as a building block in organic synthesis for the creation of various bioactive molecules. Its unique structure and reactivity allow for the development of a wide range of compounds with potential applications in different fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE is used as a pharmaceutical intermediate. Its properties make it a valuable component in the synthesis of new drugs and other biologically active compounds, contributing to the advancement of medical treatments and therapies.
Used in Drug Development:
METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE is utilized in the development of new drugs due to its potential to form various bioactive molecules. Its unique structure and reactivity enable the creation of compounds that can target specific biological pathways, potentially leading to more effective and targeted treatments for various diseases and conditions.
Used in Biologically Active Compounds:
This chemical compound is also used in the synthesis of biologically active compounds, which can have a wide range of applications in research and medicine. The versatility of METHYL 4-BROMO-1-METHYL-1H-PYRROLE-2-CARBOXYLATE allows for the exploration of its potential in various biological systems, contributing to a better understanding of its properties and applications.

Upstream product

• 124-41-4 sodium methylate 
• 184643-69-4 1-(4-bromo-1-methyl-1H-pyrrol-2-yl)-2,2,2-trichloroethan-1-one 
• 67-56-1 methanol 
• 934-05-4 methyl 4-bromo-1H-pyrrole-2-carboxylate 
• 74-88-4 methyl iodide 
• 21898-65-7 1-methyl-2-trichloroacetyl-1H-pyrrole 
• 96-54-8 N-Methylpyrrole 

Downstream Products

• 864076-02-8 methyl 4-(4-((tert-butoxycarbonyl)amino)phenyl)-1-methyl-1H-pyrrole-2-carboxylate 
• 1093624-61-3 methyl-1-methyl-4-phenyl-1H-pyrrole-2-carboxylate 
• 40740-43-0 methyl 4-cyano-1-methyl-pyrrole-2-carboxylate 

Relevant academic research and scientific papers

Synthesis of N-methylpyrrole and N-methylimidazole amino acids suitable for solid-phase synthesis

New and higher yielding synthetic routes to N-protected N-methylpyrrole and N-methylimidazole amino acids are introduced to circumvent difficulties associated with established schemes. Key steps in each synthesis include copper-mediated cross-coupling reaction to directly install a carbamate-protected 4-amine in the N-methylpyrrole derivative and effective nitration followed by a one-pot reduction/Boc protection of the amine in the synthesis of the N-Me-imidazole amino acid.

Design, Synthesis, and Fungicidal Evaluation of Novel Pyrazole-furan and Pyrazole-pyrrole Carboxamide as Succinate Dehydrogenase Inhibitors

The identification of novel succinate dehydrogenase (SDH) inhibitors represents one of the most attractive directions in the field of fungicide research and development. During our continuous efforts to pursue inhibitors belonging to this class, some structurally novel pyrazole-furan carboxamide and pyrazole-pyrrole carboxamide derivatives have been discovered via the introduction of scaffold hopping and bioisosterism to compound 1, a remarkably potent lead obtained by pharmacophore-based virtual screening. As a result of the evaluation against three destructive fungi, including Sclerotinia sclerotiorum, Rhizoctonia solani, and Pyricularia grisea, a majority of them displayed potent fungicidal activities. In particular, compounds 12I-i, 12III-f, and 12III-o exhibited excellent fungicidal activity against S. sclerotiorum and R. solani comparable to that of commercial SDHI thifluzamide and 1.

Synthesis and DNA binding properties of amide bond-modified analogues related to distamycin

Novel nitro analogues of distamycin which have trans olefins or α-diketo moiety instead of amide bond were synthesized. Their DNA binding properties studies by ethidium displacement assay and MPE footprinting experiments were also described.

Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors

A series of novel pyrazol-furan carboxamide analogues were designed, synthesized and biologically evaluated for their Akt1 inhibitory activities, as well as anti-proliferative efficacies against HCT116 and OVCAR-8 cell lines. Most compounds exhibited mode

NOVEL PYRROLE DERIVATIVES FOR THE TREATMENT OF CANCER

The invention provides a method for the treatment of cancer, which method comprises the general formula (I) wherein R1, R2, R3, R4 and W are as described herein.

GC-Targeted C8-linked pyrrolobenzodiazepine-biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models

DNA binding 4-(1-methyl-1H-pyrrol-3-yl)benzenamine (MPB) building blocks have been developed that span two DNA base pairs with a strong preference for GC-rich DNA. They have been conjugated to a pyrrolo[2,1-c][1,4]benzodiazepine (PBD) molecule to produce

PYRROLOBENZODIAZEPINES

A compound of formula (I) or a salt or solvate thereof, wherein the dotted double bond indicates the presence of a single or double bond between C2 and C3; R2 is selected from -H, -OH, =O, =CH2, -CN, -R, OR, halo, dihalo, =CHR, =CHRR', -O- SO2-R, CO2R and COR; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo; where R and R' are independently selected from optionally substituted C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R10 and R11 either together form a double bond, or are selected from H and QRQ respectively, where Q is selected from O, S and NH and RQ is H or C1-7 alkyl or H and SOxM, where x is 2 or 3, and M is a monovalent pharmaceutically acceptable cation; A is selected from (A1), (A2), (A3), (A4) or (A5) where X1 and Y1 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively; X2 and Y2 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively; Z1 is selected from O and S; Z2 is selected from CH and N; F is selected from a single bond and –(E-F1)m-; each E is independently selected from a single bond, and –C(=O)-NH-; each F1 is independently a C3-20 heteroarylene group; m is 1, 2 or 3; G is selected from hydrogen, C1-4alkyl, -C(=O)-O-C1-4alkyl, -(CH2)n-C3-20 heterocycloalkyl, and –O-(CH2)n-C3-20 heterocycloalkyl group; each n is 0-4; provided that A2 is not A2', where X1 and Y1 of A2' are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively; and provided that A3 is not A3', where X2 and Y2 of A3' are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively; B is either a single bond or (B1), where X and Y of B1 are selected from: CH and NMe; COH and NMe; CH and S; N and NMe; N and S, respectively; and R1 is C1-4 alkyl.

PYRROLOBENZODIAZEPINES

Pyrrolobenzodiazepine (PBDs) having a (1-methyl-1H-pyrrol-3- yl)phenyl based amino residue were found to be highly effective compounds having improved cytotoxicity ad DNA binding properties.

AMINO ACIDS

Compounds of formula (I): Z’ -CO-A-B-NH-Z (I) wherein: Z is H or an amino protecting group; Z’ is OH, a protected or activated hydroxyl group or C1; A is an optionally substituted C5-6 arylene group; and B is an optionally substituted C5-6 arylene group.